COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer
Assessment by EPISPOT of Circulating Tumor Cells as an Early Predictive Marker of Response to Chemotherapy and Targeted Therapy in Patients With Metastatic Colorectal Cancer in First Line of Treatment
Sponsor: Direction Générale de l'Offre de Soins
A NA clinical study on Metastatic Colorectal Cancer, this trial is completed. The trial is conducted by Direction Générale de l'Offre de Soins and has accumulated 7 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)In the aim to study a homogeneous cohort of patients, the investigators will only recruit patients in first line of treatment and treated by 5-FU (IV), IRINOTECAN et BEVACIZUMAB combination.
In the aim to study a homogeneous cohort of patients, the investigators will only recruit patients in first line of treatment and treated by 5-FU (IV), IRINOTECAN et BEVACIZUMAB combination.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Completed NA
-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Sep 2020 — Jan 2021 [monthly]
Completed NA
Status: Unknown Status → Completed · Phase: PHASE2 → NA
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2020 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Apr 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Direction Générale de l'Offre de Soins
- National Cancer Institute, France
- Roche Pharma AG
- University Hospital, Montpellier
For direct contact, visit the study record on ClinicalTrials.gov .